Bristol Myers Squibb (BMY) Prepaid Assets (2009 - 2026)
Bristol Myers Squibb's (BMY) quarterly Prepaid Assets came in at $4.2 billion in Q2 2026, down 22.76% year-over-year from $5.5 billion in Q2 2025, and down 8.16% quarter-over-quarter from $4.6 billion in Q1 2026.
Analysis
Bristol Myers Squibb (BMY) Prepaid Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Prepaid Assets for 18 consecutive years, with $4.2 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Prepaid Assets fell 22.76% year-over-year to $4.2 billion in Q2 2026; TTM through Jun 2026 was $4.2 billion, a 22.76% decrease from a year earlier, with the FY2025 full-year figure at $4.6 billion, down 17.87% from the prior year.
- Prepaid Assets was $4.2 billion for Q2 2026 at Bristol Myers Squibb, down from $4.6 billion in the prior quarter.
- Over five years, Prepaid Assets peaked at $7.2 billion in Q3 2023 and troughed at $4.2 billion in Q2 2026.
- A 5-year average of $5.5 billion and a median of $5.6 billion in 2024 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets surged 39.11% in 2022 and retreated 22.76% in 2026, its largest moves.
- Over 5 years, Prepaid Assets stood at $5.8 billion in 2022, then grew by 1.93% to $5.9 billion in 2023, then fell by 4.91% to $5.6 billion in 2024, then decreased by 17.87% to $4.6 billion in 2025, then declined by 8.48% to $4.2 billion in 2026.
- The last three Prepaid Assets figures came in at $4.2 billion (Q2 2026), $4.6 billion (Q1 2026), and $4.6 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.22 Bn |
| Mar 31, 2026 | 4.60 Bn |
| Dec 31, 2025 | 4.61 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 5.47 Bn |
| Mar 31, 2025 | 5.53 Bn |
| Dec 31, 2024 | 5.62 Bn |
| Sep 30, 2024 | 5.62 Bn |
| Jun 30, 2024 | 5.74 Bn |
| Mar 31, 2024 | 5.57 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 7.21 Bn |
| Jun 30, 2023 | 6.87 Bn |
| Mar 31, 2023 | 5.16 Bn |
| Dec 31, 2022 | 5.80 Bn |
| Sep 30, 2022 | 6.08 Bn |
| Jun 30, 2022 | 5.76 Bn |
| Mar 31, 2022 | 4.54 Bn |
| Dec 31, 2021 | 4.83 Bn |
| Sep 30, 2021 | 4.37 Bn |